Drugs / Verorab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00424944 | Jun 2007 → Jul 2008 | malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02490956 | Apr 2015 → Sep 2016 | immunodeficiency disease | Chulalongkorn University | Unknown | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1 | NCT07124156 Comparator | Mar → Jul 2026 overdue | malaria | European Vaccine Initiative | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05644067 Comparator | Aug 2023 → Apr 2024 | malaria | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 1 | NCT05135273 Comparator | Oct 2021 → Feb 2023 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT07055880 Comparator | Jul 2025 → Jan 2026 overdue | rabies | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01341704 Comparator | May → Dec 2011 | Plasmodium falciparum malaria | Vac4All | Completed | No outcome recorded |
| Phase 2 | NCT00948272 Comparator | Jul 2009 → Feb 2011 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 2 | NCT00652275 Comparator | May 2008 → Nov 2010 | Plasmodium falciparum malaria | African Malaria Network Trust | Unknown | No outcome recorded |
| Phase 3 | NCT07055295 Comparator | Mar → Dec 2026 expected | rabies | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07055893 Comparator | Mar 2026 → Jan 2027 expected | — | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04594551 Comparator | Oct 2020 → Jun 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04127786 Comparator | Oct 2019 → Mar 2020 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT03965962 Comparator | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT01339312 Comparator | Apr 2011 → Mar 2012 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verorab | “A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a...” PMID 24148575 ↗ Oct 201314“Verorab was licensed in 1985 for both pre- and post-exposure prophylaxis of rabies.” PMID 23510665 ↗ Mar 2013 “licensed purified Vero cell vaccine (PVRV; Verorab)” PMID 38478634 ↗ Jun 2024 “Group 2: Verorab + HRIG” NCT04594551 ↗ |
| Known as | PVRV | “licensed purified Vero cell vaccine (PVRV; Verorab)” PMID 38478634 ↗ Jun 20241“Verorab® (PVRV; Purified Vero Cell Vaccine)” NCT02490956 ↗ |
| Modality | Vaccine | “Anti-rabies vaccine” NCT00424944 ↗ |
| Route | Intramuscular | “0.5 ml intramuscular” NCT02490956 ↗ |